Payment overview · 2025
General Payments
$486.36
26 reported records · 6 companies
Healthcare provider profile · identity verified
Daniela Mitko Sikoski, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VALPARAISO, IN · NPI 1932160215
Verified facts
What the public records show
CMS Open Payments records show Daniela Mitko Sikoski, MD received $486.36 in general payments during 2025 across 26 reported records.
Amgen Inc. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $192.26 | 39.5% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.00 | 25.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.08 | 14.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.51 | 10.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.19 | 6.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.32 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $486.36 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $135.89 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $135.89 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $56.37 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.51 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.46 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.46 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $11.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 164 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
164 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 592 | 165 |
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 119 |
| Lisinopril | Lisinopril | 285 | 78 |
| Buspirone Hcl | Buspirone Hcl | 281 | 77 |
| Carvedilol | Carvedilol | 271 | 72 |
| Metformin Hcl | Metformin Hcl | 267 | 77 |
| Omeprazole | Omeprazole | 267 | 77 |
| Losartan Potassium | Losartan Potassium | 251 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 62 |
| Alprazolam | Alprazolam | 214 | 45 |
| Montelukast Sodium | Montelukast Sodium | 211 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 51 |
| Gabapentin | Gabapentin | 205 | 67 |
| Famotidine | Famotidine | 197 | 64 |
| Valsartan | Valsartan | 188 | 46 |
| Glimepiride | Glimepiride | 182 | 51 |
| Clonazepam | Clonazepam | 181 | 45 |
| Potassium Chloride | Potassium Chloride | 173 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 41 |
| Synthroid | Levothyroxine Sodium | 164 | 45 |
| Telmisartan | Telmisartan | 154 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 46 |
| Trazodone Hcl | Trazodone Hcl | 147 | 40 |
| Sertraline Hcl | Sertraline Hcl | 141 | 38 |
| Irbesartan | Irbesartan | 137 | 40 |
| Ezetimibe | Ezetimibe | 136 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 128 | 88 |
| Mounjaro | Tirzepatide | 123 | 32 |
| Metformin Hcl Er | Metformin Hcl | 119 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 57 |
| Ozempic | Semaglutide | 106 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 33 |
| Simvastatin | Simvastatin | 102 | 29 |
| Tramadol Hcl | Tramadol Hcl | 102 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Jardiance | Empagliflozin | 75 | 16 |
| Clonidine Hcl | Clonidine Hcl | 73 | 18 |
| Methylprednisolone | Methylprednisolone | 73 | 60 |
| Allopurinol | Allopurinol | 72 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 17 |
| Atenolol | Atenolol | 61 | 17 |
| Bupropion Xl | Bupropion Hcl | 61 | 18 |
| Furosemide | Furosemide | 56 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Methocarbamol | Methocarbamol | 52 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 21 |
| Lorazepam | Lorazepam | 39 | 12 |
| Lovastatin | Lovastatin | 39 | 11 |
| Memantine Hcl | Memantine Hcl | 37 | 12 |
| Prednisone | Prednisone | 37 | 17 |
| Ramelteon | Ramelteon | 37 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 12 |
| Betamethasone Valerate | Betamethasone Valerate | 28 | 13 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 26 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | 12 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Np Thyroid | Thyroid,pork | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $486.36 · 26 records | Amgen Inc. | AIRSUPRA, AREXVY, ELIQUIS, EVENITY, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error